Review Volume 12, Issue 5 pp 4660—4672

Adiponectin in renal fibrosis

Figure 3. Accumulative evidence about the renoprotective role of adiponectin promotes a therapeutic strategy for renal fibrosis targeting adiponectin, such as increasing the plasma adiponectin level or increasing the sensitivity of adiponectin by activating adiponectin receptors. Numerous studies have confirmed that PPAR-γ agonist compounds increase adiponectin secretion and circulating adiponectin levels in adipose tissue. And the exogenous adiponectin is also currently a hot focus for the treatment of kidney disease. In addition, AdipoRon directly activates intrarenal AdipoR1 and AdipoR2, and promotes downstream reactions, thereby restrainting renal fibrosis.